| pubmed-article:15959881 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15959881 | lifeskim:mentions | umls-concept:C0205208 | lld:lifeskim |
| pubmed-article:15959881 | lifeskim:mentions | umls-concept:C0700466 | lld:lifeskim |
| pubmed-article:15959881 | lifeskim:mentions | umls-concept:C0282448 | lld:lifeskim |
| pubmed-article:15959881 | lifeskim:mentions | umls-concept:C1708470 | lld:lifeskim |
| pubmed-article:15959881 | lifeskim:mentions | umls-concept:C1272919 | lld:lifeskim |
| pubmed-article:15959881 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15959881 | pubmed:dateCreated | 2005-7-5 | lld:pubmed |
| pubmed-article:15959881 | pubmed:abstractText | Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the approval of immediate release (IR) solid oral dosage forms containing ranitidine hydrochloride are reviewed. According to the current Biopharmaceutics Classification System (BCS), ranitidine hydrochloride should be assigned to Class III. However, based on its therapeutic and therapeutic index, pharmacokinetic properties and data related to the possibility of excipient interactions, a biowaiver can be recommended for IR solid oral dosage forms that are rapidly dissolving and contain only those excipients as reported in this study. | lld:pubmed |
| pubmed-article:15959881 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15959881 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15959881 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15959881 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15959881 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15959881 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15959881 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15959881 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15959881 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:15959881 | pubmed:issn | 0022-3549 | lld:pubmed |
| pubmed-article:15959881 | pubmed:author | pubmed-author:MidhaK KKK | lld:pubmed |
| pubmed-article:15959881 | pubmed:author | pubmed-author:ShahV PVP | lld:pubmed |
| pubmed-article:15959881 | pubmed:author | pubmed-author:JungingerH... | lld:pubmed |
| pubmed-article:15959881 | pubmed:author | pubmed-author:DressmanJ BJB | lld:pubmed |
| pubmed-article:15959881 | pubmed:author | pubmed-author:YliperttulaMM | lld:pubmed |
| pubmed-article:15959881 | pubmed:author | pubmed-author:BarendsD MDM | lld:pubmed |
| pubmed-article:15959881 | pubmed:author | pubmed-author:KortejärviHH | lld:pubmed |
| pubmed-article:15959881 | pubmed:copyrightInfo | (c) 2005 Wiley-Liss, Inc. and the American Pharmacists Association | lld:pubmed |
| pubmed-article:15959881 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15959881 | pubmed:volume | 94 | lld:pubmed |
| pubmed-article:15959881 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15959881 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15959881 | pubmed:pagination | 1617-25 | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:meshHeading | pubmed-meshheading:15959881... | lld:pubmed |
| pubmed-article:15959881 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15959881 | pubmed:articleTitle | Biowaiver monographs for immediate release solid oral dosage forms: ranitidine hydrochloride. | lld:pubmed |
| pubmed-article:15959881 | pubmed:affiliation | Orion Pharma, Research and Development, Espoo, Finland. | lld:pubmed |
| pubmed-article:15959881 | pubmed:publicationType | Journal Article | lld:pubmed |
